End-of-day quote
Pakistan S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
1,320
PKR
|
-2.24%
|
|
-5.56%
|
+9.98%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
7,234
|
7,717
|
7,304
|
8,658
|
9,240
|
11,574
|
Enterprise Value (EV)
1 |
6,979
|
8,137
|
7,815
|
8,074
|
10,639
|
10,567
|
P/E ratio
|
11.8
x
|
49.8
x
|
14.8
x
|
9.56
x
|
55.4
x
|
32.1
x
|
Yield
|
4%
|
1%
|
2.64%
|
3.34%
|
-
|
2.5%
|
Capitalization / Revenue
|
0.56
x
|
0.53
x
|
0.52
x
|
0.55
x
|
0.5
x
|
0.54
x
|
EV / Revenue
|
0.54
x
|
0.56
x
|
0.55
x
|
0.51
x
|
0.57
x
|
0.49
x
|
EV / EBITDA
|
4.24
x
|
7.83
x
|
5.09
x
|
4.61
x
|
6.97
x
|
4.53
x
|
EV / FCF
|
5.81
x
|
-516
x
|
53.5
x
|
5.6
x
|
-8.96
x
|
3.28
x
|
FCF Yield
|
17.2%
|
-0.19%
|
1.87%
|
17.8%
|
-11.2%
|
30.5%
|
Price to Book
|
1.68
x
|
1.89
x
|
1.6
x
|
1.66
x
|
1.84
x
|
2.12
x
|
Nbr of stocks (in thousands)
|
9,645
|
9,645
|
9,645
|
9,645
|
9,645
|
9,645
|
Reference price
2 |
750.0
|
800.1
|
757.3
|
897.7
|
958.0
|
1,200
|
Announcement Date
|
3/14/19
|
4/27/20
|
3/30/21
|
4/1/22
|
5/3/23
|
3/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
12,961
|
14,501
|
14,108
|
15,881
|
18,560
|
21,369
|
EBITDA
1 |
1,646
|
1,039
|
1,534
|
1,750
|
1,527
|
2,331
|
EBIT
1 |
1,305
|
685.6
|
1,196
|
1,429
|
1,245
|
2,018
|
Operating Margin
|
10.07%
|
4.73%
|
8.48%
|
9%
|
6.71%
|
9.45%
|
Earnings before Tax (EBT)
1 |
925.8
|
546.4
|
879.9
|
1,436
|
724.1
|
916.1
|
Net income
1 |
612.8
|
154.8
|
493.1
|
906
|
166.8
|
360.8
|
Net margin
|
4.73%
|
1.07%
|
3.49%
|
5.7%
|
0.9%
|
1.69%
|
EPS
2 |
63.54
|
16.05
|
51.12
|
93.93
|
17.29
|
37.41
|
Free Cash Flow
1 |
1,201
|
-15.78
|
146
|
1,441
|
-1,188
|
3,224
|
FCF margin
|
9.27%
|
-0.11%
|
1.03%
|
9.07%
|
-6.4%
|
15.09%
|
FCF Conversion (EBITDA)
|
72.97%
|
-
|
9.51%
|
82.35%
|
-
|
138.31%
|
FCF Conversion (Net income)
|
195.99%
|
-
|
29.6%
|
159.05%
|
-
|
893.49%
|
Dividend per Share
2 |
30.00
|
8.000
|
20.00
|
30.00
|
-
|
30.00
|
Announcement Date
|
3/14/19
|
4/27/20
|
3/30/21
|
4/1/22
|
5/3/23
|
3/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
420
|
510
|
-
|
1,400
|
-
|
Net Cash position
1 |
255
|
-
|
-
|
583
|
-
|
1,006
|
Leverage (Debt/EBITDA)
|
-
|
0.4042
x
|
0.3327
x
|
-
|
0.9166
x
|
-
|
Free Cash Flow
1 |
1,201
|
-15.8
|
146
|
1,441
|
-1,188
|
3,224
|
ROE (net income / shareholders' equity)
|
14.5%
|
3.69%
|
11.4%
|
18.5%
|
3.25%
|
6.87%
|
ROA (Net income/ Total Assets)
|
11.3%
|
5.53%
|
9.15%
|
9.97%
|
7.21%
|
11.4%
|
Assets
1 |
5,421
|
2,801
|
5,390
|
9,091
|
2,315
|
3,175
|
Book Value Per Share
2 |
446.0
|
424.0
|
473.0
|
541.0
|
521.0
|
567.0
|
Cash Flow per Share
2 |
26.40
|
3.190
|
5.520
|
81.30
|
24.20
|
12.20
|
Capex
1 |
338
|
392
|
485
|
307
|
573
|
287
|
Capex / Sales
|
2.61%
|
2.7%
|
3.44%
|
1.93%
|
3.09%
|
1.34%
|
Announcement Date
|
3/14/19
|
4/27/20
|
3/30/21
|
4/1/22
|
5/3/23
|
3/18/24
|
|
1st Jan change
|
Capi.
|
---|
| +9.98% | 45.71M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|